Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction.
Salivary gland dysfunction is a common side effect of cancer therapies. Salivary secretions are reduced rapidly after starting head and neck radiotherapy. Salivary gland dysfunction has also been linked to bone marrow transplantation and to cytotoxic chemotherapy. Salivary gland stimulation during radiation has been suggested as a means of reducing radiation damage. Results of an ongoing study investigating the effects of pilocarpine on radiation-induced salivary gland dysfunction suggest that parotid function was preserved, but not submandibular/sublingual function. Also, patients receiving pilocarpine had less frequent oral complaints. Further research is necessary to develop means of preventing or alleviating the salivary side effects of cancer therapies.
Clinical Investigations and Patient Care Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892.
A
A
Wolff
J C
JC
Atkinson
A A
AA
Macynski
P C
PC
Fox
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D010862:Pilocarpine / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects*; D012469:Salivary Glands / Q000187:drug effects / Q000528:radiation effects*
D000970:Antineoplastic Agents; D010862:Pilocarpine